My perspective is that at $17, a 5-fold gain off the 52 week low is a most acceptable ROI.
Looking forward 52 weeks, given the current rate of development on the already strong pipeline foundation, it should not be too surprising to see another 5-fold AVXL price increase. (My assumption is continuing positive RETT, PDD and AD news coupled with positive Fragile-x, Angelman's and undisclosed rare disease developments and more positve A3-71 news.)
So yes, given a 1-year horizon, AVXL at $17 does look undervalued to me.
We await RETT and PDD news any day now, which, if positive, (which I anticipate) could push AVXL price significantly upward, perhaps readily.
Market Data 
Markets 
AI
